Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J’s Erleada first US drug for non-metastatic prostate cancer It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and Astellas and their Xtandi (enzalutamide) product, which has also been

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer use of Xtandi to include men with early-stage prostate cancer that hasn’t spread to other areas of the body. ... responds to hormone therapy and, if approved, the new indication would move Xtandi up the treatment chain and could allow it to be used in

Dendreon appoints new R&D lead

Dendreon appoints new R&D lead Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib Gilteritinib is one of a clutch of new drugs Astellas is banking on to inject renewed growth into its revenues as prostate cancer blockbuster Xtandi (enzalutamide) starts to slow down, and

Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A Pfizer is struggling to grow sales of its new cancer drug Xtandi, the main asset in its takeover of Medivation last September. ... The US's largest drugmaker booked $141m from Xtandi (enzalutamide) in the second quarter, up from $131m in the first

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics